Want to see IKT full AI Analyst Report?
Inhibikase Therapeutics (IKT) Ownership Overview
16.63% Insiders
5.14% Mutual Funds
65.06% Other Institutional Investors
7.75% ETFs
5.42% Public Companies and
Individual Investors
The ownership structure of Inhibikase Therapeutics (IKT) stock is a mix of institutional, retail, and individual investors. Approximately 77.95% of the company’s stock is owned by Institutional Investors, 16.63% is owned by Insiders, and 5.42% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
Date | Name | Activity | Value |
|---|---|---|---|
Nov 24, 2025 | xxxxxxxxxxxxx | $2999999 |
Top Shareholders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 13,018,965 | Insider | 9.33% | 30,334,188 | |
| 8,625,000 | Institution | 6.18% | 20,096,250 | |
| 6,970,000 | Insider | 5.00% | 16,240,100 | |
| 5,938,276 | Institution | 4.26% | 13,836,183 | |
| 5,569,356 | Institution | 3.99% | 12,976,599 | |
| 4,457,218 | Institution | 3.19% | 10,385,318 | |
| 4,335,219 | Institution | 3.11% | 10,101,060 | |
| 2,315,000 | Institution | 1.66% | 5,393,950 | |
| 1,460,000 | Insider | 1.05% | 3,401,800 | |
| 1,184,285 | Institution | 0.85% | 2,759,384 |
Top Mutual Fund Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 4,335,219 | Institution | 3.11% | 10,101,060 | |
| 1,184,285 | Institution | 0.85% | 2,759,384 | |
| 349,518 | Institution | 0.25% | 814,377 | |
| 327,910 | Institution | 0.23% | 764,030 | |
| 235,414 | Institution | 0.17% | 548,515 | |
| 181,590 | Institution | 0.13% | 423,105 | |
| 127,627 | Institution | 0.09% | 297,371 | |
| 63,298 | Institution | 0.05% | 147,484 | |
| 56,309 | Institution | 0.04% | 131,200 | |
| 56,270 | Institution | 0.04% | 131,109 |
Top ETF Holders
Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| 3,764,138 | Institution | 2.70% | 8,205,821 | |
| 2,936,409 | Institution | 2.10% | 6,841,833 | |
| 1,099,534 | Institution | 0.79% | 2,561,914 | |
| 1,006,507 | Institution | 0.72% | 2,194,185 | |
| 682,422 | Institution | 0.49% | 1,487,680 | |
| 410,433 | Institution | 0.29% | 956,309 | |
| 181,908 | Institution | 0.13% | 423,846 | |
| 138,899 | Institution | 0.10% | 334,747 | |
| 109,879 | Institution | 0.08% | 239,536 | |
| 104,906 | Institution | 0.08% | 252,823 |
FAQ
Who Owns Inhibikase Therapeutics (IKT)?
According to the latest TipRanks data, approximately 65.06% of the company's stock is held by institutional investors, 16.63% is held by insiders, and 5.42% is held by retail investors.
What percentage of Inhibikase Therapeutics (IKT) stock is held by institutional investors?
According to the latest TipRanks data, approximately 65.06% of Inhibikase Therapeutics (IKT) stock is held by institutional investors.
What percentage of Inhibikase Therapeutics (IKT) stock is held by retail investors?
According to the latest TipRanks data, approximately 5.42% of Inhibikase Therapeutics (IKT) stock is held by retail investors.
Who owns the most shares of Inhibikase Therapeutics (IKT)?
Sands Capital Life Sciences Pulse Fund II, L.P. owns the most shares of Inhibikase Therapeutics (IKT).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.